A new approach for pyrazinamide susceptibility testing in mycobacterium tuberculosis

Microbial Drug Resistance

Volumn 18, Issue 4, 2012, Pages 372-375

  Zimic, Mirko ^a   Loli, Sebastian ^a   Gilman, Robert H ^a,b   Gutierrez, Andrés ^a   Fuentes, Patricia ^a   Cotrina, Milagros ^a   Kirwan, Daniela ^c   Sheen, Patricia ^a  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CARRIER PROTEIN; PYRAZINAMIDE; PYRAZINOIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CULTURE MEDIUM; INTERMETHOD COMPARISON; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARAMETERS; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTITUBERCULAR AGENTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; DRUG RESISTANCE, BACTERIAL; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, PULMONARY;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84864329441     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2011.0207     Document Type: Article

References (20)

1. Ando, H., S. Mitarai, Y. Kondo, T. Suetake, J.I. Sekiguchi, S. Kato, T. Mori, and T. Kirikae. 2010. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin. Microbiol. Infect. 16:1164-1168.
2. Campanerut, P.A., L.D. Ghiraldi, F.L. Spositto, D.N. Sato, C.Q. Leite, M.H. Hirata, R.D. Hirata, and R.F. Cardoso. 2011. Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. J. Antimicrob. Chemother. 66:1044-1046.
3. Cheng, S.J., Thibert L., Sanchez T., Heifets L., and Zhang Y. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528-532.
4. Corbett, E.L., C.J. Watt, N. Walker, D. Maher, B.G. Williams, M.C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
5. Heifets, L., and P. Lindholm-Levy. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225.
6. Konno, K., F.M. Feldmann, and W. McDermott. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
7. Louw, G.E., R.M. Warren, P.R. Donald, M.B. Murray, M. Bosman, P.D. Van Helden, D.B. Young, and T.C. Victor. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
8. Mitchison, D.A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
9. Mphahlele, M., H. Syre, H. Valvatne, R. Stavrum, T. Mannsaker, T. Muthivhi, K. Weyer, P.B. Fourie, and H.M. Grewal. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464.
10. Muthaiah, M., S. Jagadeesan, N. Ayalusamy, M. Sreenivasan, S.S. Prabhu, U. Muthuraj, K. Senthilkumar, and S. Veerappan. 2010. Molecular Epidemiological Study of pyrazinamide- resistance in clinical isolates of Mycobacterium tuberculosis from South India. Int. J. Mol. Sci. 11:2670-2680.
11. Raviglione, M.C., R. Gupta, C.M. Dye, and M.A. Espinal. 2001. The burden of drug-resistant tuberculosis and mechanisms for its control. Ann. N Y Acad. Sci. 953:88-97.
12. Scorpio, A., P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and Y. Zhang. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543.
13. Sheen, P., P. Ferrer, R.H. Gilman, J. Lopez-Llano, P. Fuentes, E. Valencia, and M.J. Zimic. 2009. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 89:109-113.
14. Steele, M.A., and R.M. Des Prez. 1988. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845-850.
15. Sun, Z., and Y. Zhang. 1999. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob. Agents Chemother. 43:537-542.
16. Vasquez-Campos, L., L. Asencios-Solis, E. Leo-Hurtado, N. Quispe-Torres, E. Salazar-Lindo, J. Bayona, and M.C. Becerra. 2004. Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994- 2001. Int. J. Tuberc. Lung Dis. 8:465-472.
17. Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: A review. Int. J. Tuberc. Lung Dis. 7:6-21.
18. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049.
19. Zhang, Y., M.M. Wade, A. Scorpio, H. Zhang, and Z. Sun. 2003. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.
20. Zimic, P., P. Fuentes, R.H. Gilman, A.H. Gutiérrez, D. Kirwan, and P. Sheen. 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis 92:84-91.